Why the study?
A multidisciplinary workshop was convened to address the unmet and clinical needs of patients with pediatric and congenital heart valve disease.
This workshop summary highlights the urgent need for a multidisciplinary, collaborative approach to innovate durable, growth-adaptive valve therapies specifically designed for pediatric patients.
The Heart Valve Collaboratory is a multidisciplinary, patient-centered community of stakeholders addressing complex problems and embracing innovation to help patients with heart valve disease achieve their fullest potential for health. The Scientific Council is composed of cardiologists, surgeons, ex-officio representatives of the Food and Drug Administration and Centers for Medicare and Medicaid Services, National Heart Lung Blood Institute, and representatives from industry partners. In October 2022, this group convened a workshop that included experts from stakeholder groups to address the unmet and clinical needs of patients with pediatric and congenital heart valve disease. The following document includes the discussion and summary of the current state of valve therapy and the needs being addressed for valve development.
No takes yet. Share an insight, caveat, or question.
Bauser‐Heaton et al. (2024) conducted a review in Pediatric and congenital heart valve disease. Pediatric heart valve therapies was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: